Andrea Roe1, Jennifer Hillman, Samantha Butts, Mathew Smith, Daniel Rader, Martin Playford, Nehal N Mehta, Anuja Dokras. 1. Department of Obstetrics and Gynecology (A.R., J.H., S.B., M.S., A.D.), Division of Reproductive Endocrinology, University of Pennsylvania, Philadelphia, Pennsylvania 19104; Division of Translational Medicine and Human Genetics (D.R.), 11-125 Translational Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and Section of Inflammation and Cardiometabolic Disease (M.P., N.N.M.), National Heart, Lung and Blood Institute, Bethesda, Maryland 20892.
Abstract
CONTEXT: Women with polycystic ovary syndrome (PCOS) have a high prevalence of cardiovascular disease (CVD) risk factors including dyslipidemia. Lipoproteins are heterogeneous, and measurement of serum lipids provides only the size of the pool and does not predict their function or composition. Recently, high-density lipoprotein cholesterol (HDL-C) function, as determined by cholesterol efflux capacity from macrophages, has been shown to be an independent predictor of subclinical CVD. OBJECTIVE: The aim of the study was to comprehensively evaluate lipoprotein profile including lipid particle size and number and cholesterol efflux capacity in PCOS to better define CVD risk. DESIGN AND SETTING: A case control study was performed at an academic PCOS center. PATIENTS: Women with PCOS (n = 124) and geographically matched controls (n = 67) were included in the study. MAIN OUTCOME MEASURES: The primary outcome was to measure HDL-C efflux capacity by an ex vivo system involving the incubation of macrophages with apolipoprotein (Apo) B-depleted serum from subjects, and the secondary outcome was to measure lipid particle size and number using nuclear magnetic resonance spectroscopy. RESULTS: Women with PCOS had significantly higher body mass index and blood pressure but similar HDL-C and low-density lipoprotein cholesterol levels compared to controls. The mean ApoA1 levels were lower, and the ApoB/ApoA1 ratio was higher in PCOS subjects compared to controls (P < .01). There were no differences in ApoB levels. Women with PCOS had an 7% decrease in normalized cholesterol efflux capacity compared to controls (P < .003). Cholesterol efflux capacity in PCOS correlated with body mass index, ApoA1, HDL-C, and the presence of metabolic syndrome. In a multivariable regression model, PCOS was significantly associated with diminished cholesterol efflux. PCOS was also associated with an atherogenic profile including an increase in large very low-density lipoprotein particles, very low-density lipoprotein (VLDL) size, and small low-density lipoprotein cholesterol particles (P < .01). CONCLUSIONS: Our novel findings of decreased cholesterol efflux and an atherogenic lipid particle number and size pattern in women with PCOS, independent of obesity, further substantiate the increased risk of CVD in this population.
CONTEXT: Women with polycystic ovary syndrome (PCOS) have a high prevalence of cardiovascular disease (CVD) risk factors including dyslipidemia. Lipoproteins are heterogeneous, and measurement of serum lipids provides only the size of the pool and does not predict their function or composition. Recently, high-density lipoprotein cholesterol (HDL-C) function, as determined by cholesterol efflux capacity from macrophages, has been shown to be an independent predictor of subclinical CVD. OBJECTIVE: The aim of the study was to comprehensively evaluate lipoprotein profile including lipid particle size and number and cholesterol efflux capacity in PCOS to better define CVD risk. DESIGN AND SETTING: A case control study was performed at an academic PCOS center. PATIENTS: Women with PCOS (n = 124) and geographically matched controls (n = 67) were included in the study. MAIN OUTCOME MEASURES: The primary outcome was to measure HDL-C efflux capacity by an ex vivo system involving the incubation of macrophages with apolipoprotein (Apo) B-depleted serum from subjects, and the secondary outcome was to measure lipid particle size and number using nuclear magnetic resonance spectroscopy. RESULTS:Women with PCOS had significantly higher body mass index and blood pressure but similar HDL-C and low-density lipoprotein cholesterol levels compared to controls. The mean ApoA1 levels were lower, and the ApoB/ApoA1 ratio was higher in PCOS subjects compared to controls (P < .01). There were no differences in ApoB levels. Women with PCOS had an 7% decrease in normalized cholesterol efflux capacity compared to controls (P < .003). Cholesterol efflux capacity in PCOS correlated with body mass index, ApoA1, HDL-C, and the presence of metabolic syndrome. In a multivariable regression model, PCOS was significantly associated with diminished cholesterol efflux. PCOS was also associated with an atherogenic profile including an increase in large very low-density lipoprotein particles, very low-density lipoprotein (VLDL) size, and small low-density lipoprotein cholesterol particles (P < .01). CONCLUSIONS: Our novel findings of decreased cholesterol efflux and an atherogenic lipid particle number and size pattern in women with PCOS, independent of obesity, further substantiate the increased risk of CVD in this population.
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Robert A Wild; Enrico Carmina; Evanthia Diamanti-Kandarakis; Anuja Dokras; Hector F Escobar-Morreale; Walter Futterweit; Rogerio Lobo; Robert J Norman; Evelyn Talbott; Daniel A Dumesic Journal: J Clin Endocrinol Metab Date: 2010-04-07 Impact factor: 5.958
Authors: Suhail A R Doi; Jasem M K Abbas; Lynne Parkinson; Jagadish Chakraborty; Abayomi O Akanji Journal: Am J Clin Pathol Date: 2008-05 Impact factor: 2.493
Authors: Leslee J Shaw; C Noel Bairey Merz; Ricardo Azziz; Frank Z Stanczyk; George Sopko; Glenn D Braunstein; Sheryl F Kelsey; Kevin E Kip; Rhonda M Cooper-Dehoff; B Delia Johnson; Viola Vaccarino; Steven E Reis; Vera Bittner; T Keta Hodgson; William Rogers; Carl J Pepine Journal: J Clin Endocrinol Metab Date: 2008-01-08 Impact factor: 5.958
Authors: Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro Journal: Clin Endocrinol (Oxf) Date: 2017-03-09 Impact factor: 3.478
Authors: W Sean Davidson; Anna Heink; Hannah Sexmith; John T Melchior; Scott M Gordon; Zsuzsanna Kuklenyik; Laura Woollett; John R Barr; Jeffrey I Jones; Christopher A Toth; Amy S Shah Journal: J Lipid Res Date: 2016-02-23 Impact factor: 5.922
Authors: Catherine Kim; Shengchun Kong; Ronald M Krauss; Frank Z Stanczyk; Srinivasa T Reddy; Belinda L Needham; Alka M Kanaya Journal: Metab Syndr Relat Disord Date: 2015-10-02 Impact factor: 1.894
Authors: Margaret C Garin; Samantha F Butts; David B Sarwer; Kelly C Allison; Suneeta Senapati; Anuja Dokras Journal: Endocrine Date: 2016-12-21 Impact factor: 3.633
Authors: E Gourgari; M Lodish; R Shamburek; M Keil; R Wesley; M Walter; M Sampson; S Bernstein; D Khurana; C Lyssikatos; S Ten; A Dobs; A T Remaley; C A Stratakis Journal: J Clin Endocrinol Metab Date: 2015-09-15 Impact factor: 5.958
Authors: Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro Journal: Endocr Rev Date: 2015-10 Impact factor: 19.871
Authors: Alana M Munger; Dominic C Chow; Martin P Playford; Nisha I Parikh; Louie Mar A Gangcuangco; Beau K Nakamoto; Kalpana J Kallianpur; Lishomwa C Ndhlovu; Cecilia M Shikuma; Nehal N Mehta Journal: AIDS Res Hum Retroviruses Date: 2014-12-29 Impact factor: 2.205